3 results
Primary:• To evaluate the effect of efgartigimod IV compared to placebo on CRESSSecondary:• To evaluate the effect of efgartigimod IV compared to placebo on the histology of the parotid gland (selected sites only)• To evaluate the safety of…
The primary objective of the study is to demonstrate a reduction in intravascular hemolysis by REGN3918 over 26 weeks of treatment in patientswith active PNH who are treatment-naive to complement inhibitor therapy or have not recently received…
The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis (ie, proportion ofpatients achieving lactate dehydrogenase (LDH) * 1.5× upper limit of normal (ULN) over 26 weeks) of…